Tarsus Pharmaceuticals, Inc. TARS Other Receivables
Other Receivables at other companies
Other financials
Where this comes from
Reported directly by Tarsus Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OtherReceivablesNetCurrent.
The official record: Tarsus Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Tarsus Pharmaceuticals, Inc.'s other receivables.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Tarsus Pharmaceuticals, Inc.'s other receivables?
- Tarsus Pharmaceuticals, Inc. (TARS) reported other receivables of $16.86M in Q1 2026.
- How has Tarsus Pharmaceuticals, Inc.'s other receivables changed year-over-year?
- Tarsus Pharmaceuticals, Inc.'s other receivables increased by 876.4% year-over-year, from $1.73M to $16.86M.
- What is the long-term trend for Tarsus Pharmaceuticals, Inc.'s other receivables?
- Over 5 years (2020 to 2025), Tarsus Pharmaceuticals, Inc.'s other receivables has grown at a 152.5% compound annual growth rate (CAGR), from $20K to $2.05M.
- What does other receivables mean?
- This represents miscellaneous claims for cash or other assets not classified under standard trade accounts receivable. It often includes tax refunds, interest receivables, or non-core operational claims. Monitoring this helps identify potential hidden liquidity issues or delays in cash conversion.